Although this finding should be taken with caution given the small size of ERCC2-low subgroup in our population, some previous data have reported a correlation between ERCC2 upregulation with a more aggressive cancer phenotype in head and neck tumors and in NSCLC cell lines, suggesting an inter-tissue variation in NER genes and chemoresistance [39–41]. The gene discussed is NR1H2; the disease is non-small cell lung carcinoma.